Document:

EX-10.6

 Exhibit 10.6 
 FIFTH OMNIBUS AMENDMENT 
 This FIFTH OMNIBUS AMENDMENT (this “Fifth
Amendment”) is made and entered into as of April 11, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). 
 WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September 24, 2011 (the
“Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into an Omnibus Amendment dated as of February 6, 2012 (the “First Amendment”), a
Second Omnibus Amendment dated as of March 5, 2012 (the “Second Amendment”), a Third Omnibus Amendment dated as of March 30, 2012 (the “Third Amendment”) and a Fourth Omnibus Amendment dated as of
April 3, 2012 (the “Fourth Amendment” and, together with the First Amendment, the Second Amendment and Third Amendment, the “Previous Amendments”), amending certain provisions of the Securities Purchase
Agreement and the Bridge Notes; 
 WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in
Section 8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on April 11, 2012, which date may be extended from
time to time by mutual written consent of the Company and the Investors; 
 WHEREAS, the Bridge Notes dated September 24,
2011 held by the Investors, as amended by the First Amendment, in Section 1.1 thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i) April 11, 2012 or (ii) an Event of Default (as defined
in the Bridge Notes); 
 WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the
Bridge Notes to extend the April 11, 2012 date; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants
herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Securities Purchase Agreement Amendment. Section 8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace “April 11,
2012” with “April 18, 2012”. 
 2. Bridge Notes Amendment. The Bridge Notes, as amended by the Previous
Amendments, are hereby further amended to replace references to “April 11, 2012” with “April 18, 2012”. 

 3. Miscellaneous. Capitalized terms used herein and not defined shall have the
meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement are incorporated herein by reference.
Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President and Chief Executive Officer
	
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President
	
	TANG CAPITAL PARTNERS, LP
		
	By:	 	     /s/ Kevin C. Tang

		 	Kevin C. Tang
		 	Managing Director
	
	RTW INVESTMENTS, LLC
		
	By:	 	     /s/ Roderick Wong

		 	Roderick Wong
		 	Managing Member

 [Signature Page to Fifth Omnibus Amendment]EX-10.7

 Exhibit 10.7 
 SIXTH OMNIBUS AMENDMENT 
 This SIXTH OMNIBUS AMENDMENT (this “Sixth
Amendment”) is made and entered into as of April 18, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation) and RXi Pharmaceuticals Corporation (formerly
RNCS, Inc.). 
 WHEREAS, the parties entered into a Securities Purchase Agreement dated as of September 24, 2011 (the
“Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into an Omnibus Amendment dated as of February 6, 2012 (the “First Amendment”), a
Second Omnibus Amendment dated as of March 5, 2012 (the “Second Amendment”), a Third Omnibus Amendment dated as of March 30, 2012 (the “Third Amendment”), a Fourth Omnibus Amendment dated as of
April 3, 2012 (the “Fourth Amendment”), a Fifth Omnibus Amendment dated as of April 11, 2012 (the “Fifth Amendment” and, together with the First Amendment, the Second Amendment, the Third Amendment, the
Fourth Amendment and the Fifth Amendment, the “Previous Amendments”), amending certain provisions of the Securities Purchase Agreement and the Bridge Notes; 
 WHEREAS, the Securities Purchase Agreement, as amended by the Previous Amendments, in Section 8.01(c) thereof provides that the Agreement may be terminated by either the Company or the Investors if
the Closing has not occurred on or before 5:00 p.m., Eastern Standard Time, on April 18, 2012, which date may be extended from time to time by mutual written consent of the Company and the Investors; 

WHEREAS, the Bridge Notes dated September 24, 2011 held by the Investors, as amended by the First Amendment, in Section 1.1
thereof each provide for a Maturity Date (as defined in the Bridge Notes) of the earlier of (i) April 18, 2012 or (ii) an Event of Default (as defined in the Bridge Notes); 

WHEREAS, the parties desire to amend such provisions of the Securities Purchase Agreement and the Bridge Notes to extend the
April 18, 2012 date; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1.
Securities Purchase Agreement Amendment. Section 8.01(c) of the Securities Purchase Agreement, as amended by the Previous Amendments, is hereby further amended to replace “April 18, 2012” with “April 30, 2012”.

 2. Bridge Notes Amendment. The Bridge Notes, as amended by the Previous Amendments, are hereby further amended to
replace references to “April 18, 2012” with “April 30, 2012”. 

 3. Miscellaneous. Capitalized terms used herein and not defined shall have the
meanings set forth in the Securities Purchase Agreement or in the Bridge Notes, in each case, as amended, as applicable. The terms and conditions set forth in Article X of the Securities Purchase Agreement are incorporated herein by reference.
Nothing herein shall constitute a waiver of any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 

[Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Sixth Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President and Chief Executive Officer
	
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President
	
	TANG CAPITAL PARTNERS, LP
		
	By:	 	     /s/ Kevin C. Tang

		 	Kevin C. Tang
		 	Managing Director
	
	RTW INVESTMENTS, LLC
		
	By:	 	     /s/ Roderick Wong

		 	Roderick Wong
		 	Managing Member

 [Signature Page to Sixth Omnibus Amendment]EX-10.8

 Exhibit 10.8 
 SEVENTH AMENDMENT AGREEMENT 
 This SEVENTH AMENDMENT AGREEMENT (this
“Seventh Amendment”) is made and entered into as of April 25, 2012, by and among Tang Capital Partners, LP, RTW Investments, LLC, Galena Biopharma, Inc. (formerly RXi Pharmaceuticals Corporation, “Galena”) and
RXi Pharmaceuticals Corporation (formerly RNCS, Inc., “RXi”). 
 WHEREAS, the parties entered into a Securities
Purchase Agreement dated as of September 24, 2011 (the “Securities Purchase Agreement”) and the Ancillary Agreements related thereto, including the Bridge Notes; 

WHEREAS, the parties entered into several Omnibus Amendments dated as of February 6, 2012, March 5,
2012, March 30, 2012, April 3, 2012, April 11, 2012 and April 18, 2012 (the “Previous Amendments”), amending certain provisions of the Securities Purchase Agreement and the Bridge Notes;

 WHEREAS, in light of certain developments with respect to litigation to which Galena is a party, RXi and the Investors wish
to be indemnified and held harmless against any losses arising out of such litigation, and Galena wishes to so indemnify RXi and the Investors; 
 WHEREAS, Galena wishes to be assured, prior to effecting the Spin-Off, that certain facts of which the Investors are presently aware would not constitute a failure of a condition to the obligations of the
Investors at the Closing; 
 WHEREAS, the parties desire to amend or waive certain other provisions of the Securities Purchase
Agreement; 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. Certain
Definitions. References herein to the “Securities Purchase Agreement” mean the Securities Purchase Agreement as amended by the Previous Amendments and by this Amendment, as the context requires. Capitalized terms used but not defined
herein have the meanings ascribed in the Securities Purchase Agreement. 
 2. Indemnification of RXi and the Investors.
Galena hereby agrees that, subject to the Closing, Galena’s indemnification obligations under Section 9.01 of the Securities Purchase Agreement shall apply to all losses, liabilities, deficiencies, costs, damages and expenses (including,
without limitation, reasonable attorneys’ fees, charges and disbursements) incurred after the Closing as a result of as a result of claims brought by any of Galena’s warrant holders solely arising out of or relating to the transactions
contemplated by the Securities Purchase Agreement. Galena further agrees to indemnify RXi to the same extent it agrees to indemnify the Investors pursuant to the foregoing sentence. Galena’s obligations under this Section 2 are subject to
all of the provisions of Article IX of the Securities Purchase Agreement. 

 2. Certain Assurances. Each of the Investors hereby agrees and represents that,
based on the information available to it, the execution and delivery of the Separation and Settlement Agreement, dated as of the Closing Date, among RXi, Galena, the Investors, Anastasia Khvorova, Ph.D. and Advirna, LLC resolves and satisfies any
and all conditions to the Closing contained in Article V of the Agreement as they relate to the employment of Dr. Khvorova by RXi or Galena or RXi’s or Galena’s prior dealings with Advirna, LLC. Each of the Investors and the other
parties further agrees and represents that the provisions of Section 4.12(a) and Section 4.13(b) solely with respect to the time limits contained therein are hereby waived by all the parties. 

3. Miscellaneous. Capitalized terms used herein and not defined shall have the meanings set forth in the Securities Purchase
Agreement as amended. The terms and conditions set forth in Article X of the Securities Purchase Agreement are incorporated herein by reference. Except as specifically set forth in Section 3 hereof, nothing herein shall constitute a waiver of
any provision of the Securities Purchase Agreement or any of the Ancillary Documents pursuant to Section 10.03 of the Securities Purchase Agreement. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the parties hereto have executed this Seventh Amendment as of the date
first above written. 
  

			
	GALENA BIOPHARMA, INC.
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President and Chief Executive Officer
	
	RXi PHARMACEUTICALS CORPORATION
		
	By:	 	   /s/ Mark J. Ahn

		 	Mark J. Ahn
		 	President
	
	TANG CAPITAL PARTNERS, LP
		
	By:	 	     /s/ Kevin C. Tang

		 	Kevin C. Tang
		 	Managing Director
	
	RTW INVESTMENTS, LLC
		
	By:	 	     /s/ Roderick Wong

		 	Roderick Wong
		 	Managing Member

 [Signature Page to Seventh Amendment]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]